Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.47 |
| ▸ | MC4R | P32245 | 6/20 | 0.46 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11994090 | 0.99 | HRH3 (0.48) | HRH3MC4RL3MBTL3L3MBTL1CCR3 | |
| SCHEMBL11994119 | 0.96 | HRH3 (0.46) | HRH3MC4RL3MBTL3L3MBTL1CCR3 | |
| SCHEMBL11968948 | 0.93 | MC4R (0.48) | HRH3MC4RL3MBTL3L3MBTL1SLC2A1 | |
| SCHEMBL11968837 | 0.92 | MC4R (0.48) | MC4R | |
| SCHEMBL11969328 | 0.91 | SIGMAR1 (0.44) | HRH3MC4RSLC2A1MEN1KMT2A | |
| SCHEMBL11969107 | 0.90 | MC4R (0.42) | MC4RSLC2A1MEN1KMT2ATACR1 | |
| SCHEMBL11994122 | 0.89 | HRH3 (0.57) | HRH3MC4RCCR3 | |
| SCHEMBL11968882 | 0.88 | HRH3 (0.56) | HRH3MC4RCCR3 | |
| SCHEMBL11968971 | 0.88 | HRH3 (0.52) | HRH3MC4RCCR3 | |
| SCHEMBL11968848 | 0.88 | MC4R (0.46) | HRH3MC4RL3MBTL3L3MBTL1SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214798-A1 | Novel Ethanediamone Hepcidine Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| US-20120214798-A1 | Novel Ethanediamone Hepcidine Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| US-20120214798-A1 | Novel Ethanediamone Hepcidine Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| EP-2475643-A1 | NOVEL ETHANE DIAMINE HEPCIDIN ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| WO-2011026959-A1 | NOVEL ETHANE DIAMINE HEPCIDIN ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011026959-A1 | NOVEL ETHANE DIAMINE HEPCIDIN ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214798-A1 | Novel Ethanediamone Hepcidine Antagonists | HAMP, SLC40A1, FTH1 | HRH3 270/4885MC4R 1684/4885L3MBTL3 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.